Opportunity
Federal Register #2026-20771
NIAID prospective exclusive license for SFTS virus antibody and diagnostic technology
Buyer
National Institutes of Health
Posted
October 09, 2026
Identifier
2026-20771
NAICS
541714, 325414
The National Institute of Allergy and Infectious Diseases (NIAID) is offering a prospective exclusive license for antibody technology targeting Severe Fever with Thrombocytopenia Syndrome (SFTS) virus. - Government buyer/licensor: Department of Health and Human Services (HHS), National Institutes of Health (NIH), NIAID; Technology Transfer and Intellectual Property Office. - Named prospective licensee: Korea National Institute of Health. - Technology: Antibodies and antigen-binding fragments that bind the SFTS virus envelope glycoproteins Gn and Gc, plus related pharmaceutical and diagnostic compositions for prevention, diagnosis, mitigation, or treatment. - License terms: Exclusive, sublicensable, and royalty-bearing; one prospective patent license is identified. - Patent reference: Korean Patent Application No. 10-2025-0196127; NIH Tracking Number E-102-2025-0. - OEMs and vendors: No commercial manufacturers, OEMs, or vendors are identified. The Korea National Institute of Health is named as the prospective licensee.
Description
The notice announces closed virtual meetings of the Center for Scientific Review at the National Institutes of Health on November 5–6, 2026. The meetings will review and evaluate grant applications across multiple scientific subject areas. They are closed to the public because discussions may disclose confidential commercial information or personal information concerning grant applicants.